» Articles » PMID: 12572843

Pathophysiology and Assessment of Neuropathic Pain in Fabry Disease

Overview
Specialty Pediatrics
Date 2003 Feb 8
PMID 12572843
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Severe neuropathic pain and hypohidrosis are important symptoms of Fabry disease, particularly in the first three decades of life. The pain is associated with a length-dependent small-fibre neuropathy that also causes a selective deficiency of cold perception. Cold exposure often accentuates the pain and worsens thermal perception. The hypohidrosis leads to poor exercise and heat tolerance. The mechanisms by which alpha-galactosidase A deficiency causes these physiological abnormalities are poorly understood. The stored glycolipid (globotriaosylceramide) may interfere with the function of cellular membrane proteins, such as ion channels, or may lead to cytotoxicity. The characteristic neuropathic pain can be symptomatically treated with various types of anticonvulsant drugs, such as carbamazepine. Improvement in neuropathic pain as a primary outcome measure has been useful in demonstrating that enzyme replacement therapy is effective in improving pain-related quality of life in Fabry disease.

Conclusions: The dysfunction of the peripheral nervous system is easily assessable and more readily reversible with specific therapy than the destructive processes that occur in organs such as the kidney. In future, therefore, it is likely that neuropathic pain, quantitative sensory testing and hypohidrosis will serve as clinical outcome measures for studies of specific and effective therapies for Fabry disease.

Citing Articles

Expanding the Neurological Phenotype of Anderson-Fabry Disease: Proof of Concept for an Extrapyramidal Neurodegenerative Pattern and Comparison with Monogenic Vascular Parkinsonism.

Zedde M, Romani I, Scaravilli A, Cocozza S, Trojano L, Ragno M Cells. 2024; 13(13.

PMID: 38994983 PMC: 11240674. DOI: 10.3390/cells13131131.


Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson-Fabry Disease.

Tuttolomondo A, Baglio I, Riolo R, Todaro F, Parrinello G, Miceli S Int J Mol Sci. 2024; 25(1).

PMID: 38203231 PMC: 10779326. DOI: 10.3390/ijms25010061.


Left to themselves: Time to target chronic pain in childhood rare diseases.

Sieberg C, Lebel A, Silliman E, Holmes S, Borsook D, Elman I Neurosci Biobehav Rev. 2021; 126:276-288.

PMID: 33774086 PMC: 8738995. DOI: 10.1016/j.neubiorev.2021.03.008.


Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.

Do H, Park S, Im I, Seo D, Yoo H, Go H EBioMedicine. 2020; 52:102633.

PMID: 31981984 PMC: 6992938. DOI: 10.1016/j.ebiom.2020.102633.


Neuro-Otological and Peripheral Nerve Involvement in Fabry Disease.

Carmona S, Weinschelbaum R, Pardal A, Marchesoni C, Zuberbuhler P, Acosta P Audiol Res. 2017; 7(2):176.

PMID: 28794847 PMC: 5534773. DOI: 10.4081/audiores.2017.176.